Drugs / BRY812
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06038058 | Oct 2023 → Aug 2028 expected | cancer | BioRay Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07311538 | Dec 2025 → Dec 2027 expected | female reproductive organ cancer | BioRay Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRY812 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06038058 ↗ |
| Route | Intravenous | “BRY812 for injection will be administered by intravenous drip” NCT06038058 ↗ |